Wahid Ali

Prof. Wahid Ali

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 May 2022 in Cureus
Verified
Journal Article
Open access
SVSapana Verma
Sapana Verma
ASAnurag Kishor Singh
Anurag Kishor Singh
GYGeeta Yadav
Geeta Yadav
RKRashmi Kushwaha
Rashmi Kushwaha
WAWahid Ali
Wahid Ali
USU.S. Singh
U.S. Singh
Tumor necrosis factor-alpha (TNF-α) is a pleiotropic cytokine that facilitates malignant cells in immune evasion, survival, and treatment resistance by generating a favorable milieu for them. It is shown to be ectopically produced by malignant/leukemic and immune cells in the tumor microenvironment, providing a tumor-supportive environment and playing an important part in the establishment and progression of malignant cells. It is linked to hyperleukocytosis, high blast count, and poor clinical outcomes in acute leukemia (AL). Considering the varied role and different expression patterns of tumor necrosis factor-alpha in acute leukemia and its clinical relevance, the present study was planned to monitor the level of tumor necrosis factor-alpha in patients with acute leukemia and its correlation with disease outcome. The aim of this study was to monitor the level of tumor necrosis factor-alpha in patients with acute leukemia at the time of diagnosis and after induction chemotherapy. The study included cases classified as acute leukemia based on morphological examination, bone marrow analysis, and flow cytometry. In all patients with acute leukemia (n = 90) and controls (n = 10), the serum tumor necrosis factor-alpha level was measured using a Diaclone Human ELISA kit (Diaclone, Besancon, France) (solid phase sandwich ELISA) at diagnosis and after induction chemotherapy. Tumor necrosis factor-alpha levels were substantially higher in T-acute lymphoblastic leukemia (T-ALL) cases, followed by acute myeloid leukemia (AML) and B-acute lymphoblastic leukemia (B-ALL), at the time of diagnosis, compared to the control. A significant reduction in serum tumor necrosis factor-alpha level was seen in patients with acute leukemia after induction phase chemotherapy (P < 0.05). Tumor necrosis factor-alpha levels were considerably reduced (P < 0.001) in the majority of acute leukemia cases after the induction phase, while high tumor necrosis factor-alpha levels were positively correlated with incomplete remission status in the remaining cases. Tumor necrosis factor-alpha is involved in the progression of acute leukemia and its relapse. High levels of tumor necrosis factor-alpha are linked to leukocytosis, high blast counts, and worse survival in patients with acute leukemia. Monitoring of tumor necrosis factor-alpha may be helpful in patients with acute leukemia in view of available antitumor necrosis factor-alpha therapy.

24 August 2016 in Parasite Immunology
Verified
Journal Article
Closed access
PDF file
Rahul ShivahareRahul Shivahare
Rahul Shivahare
WAWahid Ali
Wahid Ali
USU. S. Singh
U. S. Singh
SNS. M. Natu
S. M. Natu
SKSanjay Khattri
Sanjay Khattri
SGSuman Gupta
Suman Gupta

1 April 2021 in Prostaglandins & Other Lipid Mediators
Verified
Journal Article
Closed access
SMSridhar Mishra
Sridhar Mishra
ARAliya Rizvi
Aliya Rizvi
APAkshay Pradhan
Akshay Pradhan
MPMarco A. Perrone
Marco A. Perrone
WAWahid Ali
Wahid Ali


26 November 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SKSandeep Kumar
Sandeep Kumar
WAWahid Ali
Wahid Ali
SMSridhar Mishra
Sridhar Mishra
APAkshyaya Pradhan
Akshyaya Pradhan
RSRishi Sethi
Rishi Sethi
Marco Alfonso PerroneMarco Alfonso Perrone
Marco Alfonso Perrone
Background: Cardiac troponin is the best marker to diagnose acute coronary syndrome (ACS). However, early diagnosis using markers for plaque instability may be of significance. Soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) plays an important role in the pathogenesis of atherosclerosis plaque rupture and may be a potential biomarker of coronary artery disease (CAD), including ACS. The current study aims to evaluate sLOX-1 levels in the sera of patients with ACS as an independent marker of CAD with other established diagnostic markers and assess its level before and after percutaneous intervention (PCI) in predicting the risk of future recurrence of ACS. Methods: Peripheral blood was obtained from a total of 160 patients, including patients who underwent coronary angiography (n = 18, group I), patients of stable CAD who underwent percutaneous intervention (n = 50, group II), patients of the acute coronary syndrome (n = 64, group III), and healthy controls (n = 28, group IV). A serum sLOX-1 concentration was measured by the enzyme-linked immunosorbent assay (ELISA). Results: The results obtained showed a statistically significant raised level of sLOX-1 in pre/post PCI patients of stable CAD/ACS with male preponderance. The area under the curve for sLOX-1 was 0.925 for cases that are discriminated from controls with sensitivity and specificity of 87.88 and 100%, respectively. SLOX-1 showed 100% sensitivity and specificity in the discrimination of the stable CAD that underwent PCI vs. control with an AUC of 1.00. The recurrence of coronary artery disease was observed in 9 out of 132 (6.8%) cases. The post-interventional sLOX-1 level was significantly different and higher in recurrent cases (p = 0.027) of ACS/CAD. Conclusions: sLOX-1 was a useful biomarker of stable CAD/ACS and has a potential in the risk prediction of a future recurrence of coronary artery disease.

21 August 2022 in Indian Journal of Clinical Biochemistry
Verified
Journal Article
Closed access
PDF file
SMSridhar Mishra
Sridhar Mishra
DDDevanshi B. Dubey
Devanshi B. Dubey
KAKrachi Agarwal
Krachi Agarwal
SVShweta Verma
Shweta Verma
NSNida Shabbir
Nida Shabbir
WAWahid Ali
Wahid Ali